Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short Duration Therapy for Candidemia
NCT06859671Phase 3Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2025
- Primary completion
- Sep 2027
01
Overview
Phase 3, randomised, open-label trial in candidemia (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: All-cause mortality at Day 28. Planned start Jul 2025; status: not yet recruiting.
02
Conditions
candidemia
Beyond the preview
Go deeper on NCT06859671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06859671.